DEVELOPMENT OF NOVEL THERAPIES
DEVELOPMENT OF NOVEL DIAGNOSTIC AGENTS
We develop novel smart drug delivery systems, immunonanotherapies, supercharged antibody drug conjugates, and novel small molecules. Our expertise focuses on multiple myeloma and breast cancer models, however, we explore novel research opportunies as well as they arise.
We develop novel imaging contrast agents based on nanomedicine, including immunoPET and immunonanoPET agents, as well as immunonanoMRI agents for early diagnostic of cancers.
Our first focus is to translate all of our preclinical work into clinical trials, with the ultimate aim of improving cancer patients treatments. With the expertise of our clinicists, we are currently validating novel nano-based therapeutics for tumor sensitization, novel biosimilars for breast cancer treatments, and novel monoclonal antibodies in various ongoing Phase I/II clinical trials.